Mifegyne (Mifepristone)

Mifepristone competitively blocks progesterone receptors in the uterus, causing the decidua to break down and the embryo to detach. By sensitising the uterus to prostaglandins, it also enhances uterine contractions when a prostaglandin analogue such as misoprostol is given.

The specific dose of Mifegyne is determined by the prescribing clinician based on the indication, gestational age and local protocol. In most approved regimens a single 200 mg oral tablet is administered, but the exact schedule must be confirmed by a qualified health professional.

Mifegyne is contraindicated in ongoing pregnancy beyond the intended medical termination and is classified as Pregnancy Category X. It is also not recommended for breastfeeding mothers because the drug can be excreted in breast milk and may affect the infant.

To request Mifegyne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for early medical abortion is methotrexate, which works by inhibiting cell division rather than blocking progesterone receptors. Mifegyne provides a faster onset of action and is typically used in combination with misoprostol, offering a more predictable and shorter treatment course compared with methotrexate‑based protocols.

Mifegyne tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Mifegyne is taken orally as a single tablet with water under direct medical supervision. After the initial dose, a prostaglandin analogue such as misoprostol is usually prescribed to complete the abortion process, following the clinician’s specific protocol.

Serious risks include heavy or prolonged vaginal bleeding, infection leading to sepsis, severe allergic reactions, liver injury, uterine rupture and thromboembolic events. Patients should seek immediate medical attention if they experience signs of these complications.

Mifegyne should not be used by individuals with known adrenal insufficiency, chronic corticosteroid therapy, anticoagulant treatment, severe anemia, an intrauterine device in place, or a confirmed allergy to mifepristone or any tablet excipients. It is also contraindicated in pregnancies beyond 10 weeks gestation.